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Conclusion: Reduced BMD and minimal trauma 
fractures are both features of HIES, but the degree 
of osteopenia does not correlate with fractures, 
nor is there Laboratory evidence of increased bone 
turnover. 
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HIV Treatment Induced 
Hypogammaglobulinemia - Unmasked Common 
Variable Immune Deficiency (CVlD) 
O. Tsoukas*. McGill University Health Centre 
Immune Deficiency Treatment Centre, 1650 Cedar 
Ave., Room A5-140 Montreal, Quebec H3G 1A4, 
Canada 
Background: OVID is a very heterogeneous syn- 
drome that is characterized by tow immunogtobutin 
production, impaired specific antibody responses 
to pathogens, recurrent bacterial infections, au- 
toimmune abnormalities and sptenomegaty. Causes 
for OVID include: failure of B celt maturation, aL- 
tered somatic hypermutation, defective celt mem- 
brane signaling, T celt abnormalities, reduced OD40 
tigand expression, inducible co-stimuLator protein 
(IOOS), and L-setectin and defects in tumor necro- 
sis factor receptor super family members. HIV in- 
fection induces abnormalities intrinsic to B ceLLs 
including hypergammagtobutinemia, increases au- 
toantibody LeveLs, activation markers and risk for 
B celt tymphoma. Despite the potyctonat hyper- 
gammagtobutenemia, paradoxicaLLy HIV infection 
results in poor specific antibody responsiveness to 
vaccination. In the world Literature, 4 patients with 
CVID have been reported that have had a reversal 
of hypogammagtobutinemia and improved antibody 
production as a result of HIV infection. We describe 
a fifth such patient whose antibody production was 
normal while infected with HIV yet declined as a 
result of antiretrovirat herapy (ART). 
Objective: To describe how HIV therapy unmasked 
hypogammagtobutinemia n this patient with HIV 
and OVID. 
Method: The Immune Deficiency Treatment Centre 
(IDTO) actively foLLows more than 700 persons with 
HIV and 45 with OVID. One person has both HIV 
and OVID. ParadoxicaLLy the patient was welt and 
asymptomatic prior to beginning potent ART. Within 
2 weeks of beginning treatment, his immunogtob- 
utin LeveLs felt dramaticaLLy and he developed bac- 
teria[ pneumonia and diarrhea. 
Results: In addition to tow immunogtobutin serum 
LeveLs, the patient had a B celt phenotype consis- 
tent with almost no memory B ceLLs. The impact of 
HIV therapy is shown in the table. 
Treatment NONE ART 
IVIG 
Date 04/2004 08/2004 06/2005 07/2005 09/2005 12/2005 
HIV-1 RNAcopies/m[ 111,000 107,800 175,000 976 <50 <50 
CD4 ce[[s/mm 3 407 290 100 130 96 225 
IgG (range 7-18g/L) 7.20 5.26 3.92 8.98 8.90 
IgA (range 0.7-5.0g/L) 1.10 1.10 0.51 0.53 0.53 
IgM (range 0.4-2.4g/L) 0.55 0.55 <0.24 <0.24  <0.24 
Conclusion: Understanding the recovery of anti- 
body production in a patient with CVID as a result 
of HIV infection, or the toss of immunogtobutin 
production in HIV infected patients with CVID who 
begin ART, may Lead to the identification of factors 
important in the pathogenesis of CVID. Studies of 
viral and immune factors in this patient are being 
initiated. 
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Novel TTF1 Mutation in a Patient with 
Hypothyroidism, Chorea and Mild IgA Deficiency 
H. Ettoumi*, G. Uze[, V. Anderson, S.M. HoLLand. 
Laboratory of Clinical Infectious Diseases, NIAID, 
NIH, Bethesda, MD, USA 
Background: Congenital hypothyroidism is caused 
by deveLopmentaL defects of the thyroid gland. 
Associated neuroLogicaL symptoms are due to the 
Lack of thyroid hormone in the developing brain. 
Here, we report a 34-year-oLd Caucasian woman 
with recurrent bronchitis, a LifeLong history of 
"cLumsiness" and "ataxia" without cognitive de- 
veLopmentaL delay. She had been diagnosed with 
hypothyroidism, and had been variously character- 
ized as having trunca[ ataxia, myoctonic dystonia, 
and factitious movement disorder. Previous evaLua- 
tion had shown a miLdLy diminished IgA (60% of the 
Lower Limit of normaL), but normal IgG and IgM. IgE 
was not elevated. 
History: The family history was remarkable. Her 
paternal grandfather had had "ataxia" and mild 
speech delay. Her father had had "cLumsiness" 
starting in childhood with a right foot drop. Her 
39-year-oLd brother was oxygen dependent due to 
severe pulmonary fibrosis, recurrent pneumonias 
and a similar neuroLogicaL disorder. Her frater- 
nal twin sister had a similar early onset neuro- 
Logical disorder and died of staphyLococcaL sepsis 
foLLowing Caesarean section delivery of a baby 
girL. The daughter of her deceased sister had the 
same neuroLogicaL disorder with onset in infancy. 
At[ affected adults had hypothyroidism and tow 
IgA LeveLs, similar to the index patient. In view 
of the famiLiaL consteLLation of neurotogic disor- 
der, hypothyroidism, and pulmonary fibrosis, we 
Looked for mutations in thyroid transcription fac- 
tor 1 (TTF-1, TITF1, Nkx2.1). TTF1 is an epitheLiaL 
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specific homeodomain protein that plays an impor- 
tant rote in tung and thyroid morphogenesis. Mice 
with complete TTF1 deficiency Lack thyroid, Lungs, 
pituitary, with defects in the ventral forebrain. 
Results: A heterozygous deletion of 2bp from 
exon 2 was found (183 detAC), Leading to an eLon- 
gated missense protein Lacking the homeobox do- 
main. TTF-1 controls the expression of an array of 
genes including BMP-4, surfactant proteins, among 
others. InterestingLy, tow expression of the tu- 
mor necrosis factor receptor family member TACI 
had been found in the patient's peripheral blood 
monocytes. Mutations in TACI had been recently 
reported to cause IgA deficiency. 
Conclusions: It is apparent that TTF1 has a signif- 
icant regulatory rote in immunity, and appears to 
be involved in IgA and possibly IgG production. This 
rare autosoma[ dominant disorder is a paradigm for 
complex regulation of immune and somatic genes 
by a single transcription factor. 
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Infections associated with Tumor Necrosis 
Factor Blockade in Chronic Granulomatous 
Disease 
G. UzeL*, T. HeLLer, S.M. HoLLand. NIH, 
Bethesda, MD, USA 
Introduction: Chronic granuLomatous disease (CGD), 
a genetic disorder of phagocyte NADPH oxidase, 
predisposes to infections and inflammatory com- 
plications, including severe colitis. Infliximab, a 
chimeric monocLonaL antibody to tumor necrosis 
factor-aLpha (TNF~), closes fistulas and induces and 
maintains remission in inflammatory bowel disease 
(IBD). We have used infliximab for fistuLizing and 
active IBD in 3 patients with CGD. 
Methods: Patients had progressed espite therapy 
with steroids, ASA derivatives, and antimicrobiaLs. 
BaseLine radioLogic and endoscopic evaluations pre- 
ceded infliximab at a dose of 5 mg/kg IV every 4 
weeks. ALL patients received 6-MP, prednisone and 
a saLicyLic acid derivative, as weLL as TMP/SMX and 
itraconazoLe or voriconazoLe prophylaxis. 
Results: Patient 1, a 16 year old girl with p47phox 
deficient CGD and colitis, presented with a painful 
rectovagina[ fistula. Her fistula closed and symp- 
toms resolved on infliximab. Around her 8th dose 
of infliximab, she developed Burkholderia cepacia 
pneumonia. Antibacterial therapy was successfuL. 
Patient 2 is a 20 year old man with gp91phox 
deficient CGD who had Long standing history of pe- 
riana[ abscess and fistulae along with uncontroLLed 
IBD. His symptoms and fistulae regressed on inflix- 
imab. After the 5th dose, he developed a symp- 
tomatic perirecta[ abscess, possibly due to closure 
of the draining fistula, with associated inguinal [ym- 
phadenitis. Lymph node culture grew Candida lusi- 
taniae. Patient 3 is a 17 year old boy with gp91 phox 
deficient CGD who had a rectovesica[ fistula and 
active IBD. Infliximab remitted symptoms and re- 
duced the fistula. After the 3rd dose he developed 
Burkholderia gladioli sepsis, which responded to 
standard therapy. A diverting coLostomy and 2 more 
doses of infliximab ted to closure of the fistula. 
After the 5th dose, an asymptomatic Paecilomyces 
variotti pneumonia Led to cessation of infliximab. 
Conclusions: We have used infliximab in patients 
with CGD for severe fistuLizing IBD. In 3 patients 
and 18 infusions, we encountered the typical CGD 
pathogens, Burkholderia nd Paecilomyces, but not 
other opportunistic pathogens, such as mycobacte- 
ria. Infliximab was highly effective in the treatment 
of refractory CGD associated colitis. However, we 
noted an increased rate of typical CGD infections. 
TNF blockade in CGD should be used with caution 
and with extremely close surveiLLance for infection. 
